SG11202109002XA - Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy - Google Patents

Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy

Info

Publication number
SG11202109002XA
SG11202109002XA SG11202109002XA SG11202109002XA SG11202109002XA SG 11202109002X A SG11202109002X A SG 11202109002XA SG 11202109002X A SG11202109002X A SG 11202109002XA SG 11202109002X A SG11202109002X A SG 11202109002XA SG 11202109002X A SG11202109002X A SG 11202109002XA
Authority
SG
Singapore
Prior art keywords
combination
plasma cell
pathway inhibitors
treating allergy
cell ablation
Prior art date
Application number
SG11202109002XA
Inventor
Seblewongel Asrat
Andre Limnander
Jamie Orengo
George D Yancopoulos
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202109002XA publication Critical patent/SG11202109002XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG11202109002XA 2019-03-21 2020-03-20 Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy SG11202109002XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962822022P 2019-03-21 2019-03-21
US202062957550P 2020-01-06 2020-01-06
PCT/US2020/023988 WO2020191346A1 (en) 2019-03-21 2020-03-20 Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy

Publications (1)

Publication Number Publication Date
SG11202109002XA true SG11202109002XA (en) 2021-09-29

Family

ID=70465230

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109002XA SG11202109002XA (en) 2019-03-21 2020-03-20 Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy

Country Status (15)

Country Link
US (1) US11964016B2 (en)
EP (1) EP3941589A1 (en)
JP (1) JP2022526738A (en)
KR (1) KR20210143246A (en)
CN (1) CN113597328A (en)
AU (1) AU2020240132A1 (en)
BR (1) BR112021018627A2 (en)
CA (1) CA3132587A1 (en)
CL (1) CL2021002410A1 (en)
CO (1) CO2021013993A2 (en)
IL (1) IL286470A (en)
MA (1) MA55372A (en)
MX (1) MX2021011141A (en)
SG (1) SG11202109002XA (en)
WO (1) WO2020191346A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI633891B (en) 2013-06-04 2018-09-01 再生元醫藥公司 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
TWI682781B (en) 2013-07-11 2020-01-21 美商再生元醫藥公司 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
CN106062000B (en) 2014-02-28 2021-05-28 瑞泽恩制药公司 Methods of treating skin infections by administering IL-4R antagonists
MA46098A (en) 2016-09-01 2019-07-10 Regeneron Pharma METHODS FOR PREVENTING OR TREATING ALLERGY BY GIVING AN IL-4 R ANTAGONIST
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
EP3793597A1 (en) 2018-05-13 2021-03-24 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
MX2021000488A (en) * 2018-07-19 2021-04-12 Regeneron Pharma BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF.
CA3147068A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
JP2023505218A (en) * 2019-12-06 2023-02-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
KR20230130681A (en) * 2021-01-08 2023-09-12 리제너론 파아마슈티컬스, 인크. Method of treating peanut allergy by administration of IL-4R antagonist and method of strengthening peanut allergen-specific immunotherapy
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
BR9205967A (en) 1991-05-03 1994-07-26 Seragen Inc Interleukin receptor-labeled molecules treatment of inflammatory arthritis
JP3315427B2 (en) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 Dermatitis treatment
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (en) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Recombinant antibody il4 used for treatment of disorders associated with function of il4
DE69931377T2 (en) 1998-09-18 2007-05-10 Dynavax Technologies Corp., Berkeley PROCESS FOR TREATING IG-E ASSOCIATED DISEASES AND COMPOSITIONS FOR USE THEREOF IN THESE METHODS
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP3190126A1 (en) 2000-05-26 2017-07-12 Immunex Corporation Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
DE60130466T2 (en) 2000-07-26 2008-06-12 Hououdou Co. Ltd. ANTIPRURITIC COMPOSITIONS AND WOUND HEALING COMPOSITIONS
MXPA03005643A (en) 2000-12-22 2003-10-06 Nestle Sa Induction of tolerance.
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
WO2002092125A1 (en) 2001-05-11 2002-11-21 Novartis Ag Compositions for use in treating ige-associated disorders
US20050074462A1 (en) 2001-05-23 2005-04-07 Duotol Ab Supression of allergic reactions by transdermal administration of allergens conjugated to cholera toxin or fragments thereof
ATE517855T1 (en) 2001-11-30 2011-08-15 Biogen Idec Inc ANTIBODIES TO CHEMOTACTIC MONOCYTE PROTEINS
ES2327830T3 (en) 2002-03-29 2009-11-04 Schering Corporation ANTI-INTERLEUQUINA-5 HUMAN MONOCLONAL ANTIBODIES AND METHODS AND COMPOSITIONS CONTAINING THEM.
MXPA05005528A (en) 2002-11-26 2006-04-05 Alk Abello As Pharmaceutical allergen product.
ES2566778T3 (en) 2003-02-01 2016-04-15 Tanox, Inc. High affinity anti-human IgE antibodies
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
AU2004290017B2 (en) 2003-11-07 2012-05-03 Immunex Corporation Antibodies that bind interleukin-4 receptor
US7884054B2 (en) 2003-12-22 2011-02-08 Amgen Inc. Methods for identifying functional antibodies
JP4943161B2 (en) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド Treatment of cancer with a novel anti-IL13 monoclonal antibody
EP1723173B1 (en) 2004-02-27 2008-05-14 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypeptides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
AR050044A1 (en) 2004-08-03 2006-09-20 Novartis Ag IL-4 SPECIFIC ANTIBODY
JP5234445B2 (en) 2004-10-05 2013-07-10 源一郎 杣 Drug
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
MX2007013609A (en) 2005-05-06 2008-01-24 Zymogenetics Inc Il-31 monoclonal antibodies and methods of use.
WO2006124451A2 (en) 2005-05-11 2006-11-23 Centocor, Inc. Anti-il-13 antibodies, compositions, methods and uses
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
WO2007107349A1 (en) 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treament of cancer
MX2008014804A (en) 2006-06-02 2009-01-27 Regeneron Pharma High affinity antibodies to human il-6 receptor.
JP4221018B2 (en) 2006-08-31 2009-02-12 トヨタ自動車株式会社 Head protection airbag device
ES2902063T3 (en) 2006-09-08 2022-03-24 Abbvie Bahamas Ltd Interleukin-13 binding proteins
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101522716B (en) 2006-10-02 2013-03-20 瑞泽恩制药公司 High affinity human antibodies to human IL-4 receptor
SI2132230T1 (en) * 2007-03-22 2014-07-31 Genentech, Inc. Apoptotic anti-ige antibodies binding the membrane-bound ige
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (en) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergy vaccine formulation for mucosal administration
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
EP2376656A4 (en) 2008-12-01 2012-05-16 Cincinnati Children S Hospital Medical Ct Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
WO2010120511A2 (en) 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Method of treating respiratory disorders
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
CN102596237A (en) 2009-09-07 2012-07-18 Dbv技术公司 Method of treating eosinophilic esophagitis
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
WO2011108008A2 (en) 2010-03-04 2011-09-09 Transgene Biotek Ltd. Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
US20120164080A1 (en) 2010-06-24 2012-06-28 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2012049278A1 (en) 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
TR201802772T4 (en) * 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Multi-specific antigen binding molecule with alternative function for the function of blood coagulation factor VIII.
RU2453303C1 (en) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Pharmaceutical composition for atopic dermatitis
EP2661631A4 (en) 2011-01-06 2014-05-21 Childrens Hosp Medical Center Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
WO2012177945A2 (en) 2011-06-21 2012-12-27 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2763683A1 (en) 2011-10-06 2014-08-13 N.V. Nutricia Treatment of eosinophilic esophagitis
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
BR112014014558A8 (en) 2011-12-16 2017-07-04 Atopix Therapeutics Ltd pharmaceutical composition, use of a crth2 antagonist and a proton pump inhibitor, and kit for the treatment of eosinophilic esophagitis
WO2013116287A1 (en) * 2012-01-31 2013-08-08 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
ES2900342T3 (en) 2012-08-21 2022-03-16 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
WO2014039461A1 (en) 2012-09-07 2014-03-13 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2014059178A1 (en) 2012-10-10 2014-04-17 Rhode Island Hospital Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis
TW201425336A (en) 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
JP6636803B2 (en) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Method for selection of antibodies to BCMA
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh UNION MOLECULES FOR BCMA AND CD3
WO2014165771A2 (en) 2013-04-05 2014-10-09 Genentech, Inc. Anti-il-4 antibodies and bispecific antibodies and uses thereof
TWI633891B (en) 2013-06-04 2018-09-01 再生元醫藥公司 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
JP6463351B2 (en) 2013-06-21 2019-01-30 サノフィ・バイオテクノロジー Method for treating nasal polyposis by administration of an IL-4R antagonist
TWI682781B (en) 2013-07-11 2020-01-21 美商再生元醫藥公司 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
RU2552929C1 (en) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Pharmaceutical composition, containing derivatives of glutarimides, and their application for treatment of eosinophilic diseases
KR20220029765A (en) 2014-02-21 2022-03-08 사노피 바이오테크놀로지 Methods for treating or preventing asthma by administering an il-4r antagonist
CN106062000B (en) 2014-02-28 2021-05-28 瑞泽恩制药公司 Methods of treating skin infections by administering IL-4R antagonists
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN107206073A (en) 2014-11-14 2017-09-26 赛诺菲生物技术公司 By applying the method that IL 4R antagonists are used to treat the chronic nasosinusitis with nasal polyp
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
SI3628687T1 (en) 2014-12-12 2021-12-31 2Seventy Bio, Inc. Bcma chimeric antigen receptors
US10647778B2 (en) 2015-02-09 2020-05-12 University Of Florida Research Foundation, Incorporated Bi-specific chimeric antigen receptor and uses thereof
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
PE20171653A1 (en) 2015-04-13 2017-11-13 Pfizer CHEMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
CN114773476A (en) 2015-04-13 2022-07-22 辉瑞公司 Therapeutic antibodies and their use
NL2014882B1 (en) 2015-05-29 2017-01-31 Citeq B V Allergy-specific immunotherapy compositions for use in the treatment of house-dust mite allergy.
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
PE20180795A1 (en) 2015-08-17 2018-05-09 Janssen Pharmaceutica Nv ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND BCMA AND CD3, AND THE USE OF THEM
BR112018011228A2 (en) 2015-12-01 2019-01-15 Glaxosmithkline Ip Dev Ltd combination treatments and their uses and methods
US11090334B2 (en) 2016-01-29 2021-08-17 Med Manor Organics (P) Ltd. Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
KR20180103084A (en) 2016-02-03 2018-09-18 암젠 리서치 (뮌헨) 게엠베하 BCMA and CD3 bispecific T cell engrafting antibody constructs
CN108778329B (en) 2016-02-17 2022-09-16 西雅图基因公司 BCMA antibodies and their use to treat cancer and immune disorders
CA3014202A1 (en) 2016-02-19 2017-08-24 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
SI3436079T1 (en) 2016-04-01 2022-01-31 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
JP6202480B1 (en) 2016-04-22 2017-09-27 マツダ株式会社 Vehicle behavior control device
SG11201810697QA (en) 2016-06-07 2018-12-28 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
AU2017281034B2 (en) 2016-06-21 2024-03-14 Teneobio, Inc. CD3 binding antibodies
TWI777515B (en) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 Methods of treating eosinophilic esophagitis
MA46098A (en) 2016-09-01 2019-07-10 Regeneron Pharma METHODS FOR PREVENTING OR TREATING ALLERGY BY GIVING AN IL-4 R ANTAGONIST
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
MX2019003235A (en) 2016-09-22 2019-07-08 Regeneron Pharma Methods for treating severe atopic dermatitis by administering an il-4r inhibitor.
BR112019008426A2 (en) 2016-11-02 2019-09-03 Engmab Sarl bispecific antibody against bcma and cd3 and an immunological drug for combined use in the treatment of multiple myeloma
KR20240005168A (en) 2016-11-04 2024-01-11 2세븐티 바이오, 인코포레이티드 Anti-bcma car t cell compositions
CA3052779A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018201051A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
GB201709508D0 (en) 2017-06-15 2017-08-02 Autolus Ltd Chimeric antigen receptor
JP7288405B2 (en) 2017-06-30 2023-06-07 アメリカ合衆国 Anti-B cell maturation antigen chimeric antigen receptor with human domain
CR20200100A (en) 2017-08-01 2020-05-09 Medimmune Llc Bcma monoclonal antibody-drug conjugate
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
EP3793597A1 (en) 2018-05-13 2021-03-24 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
CN112261954A (en) 2018-06-14 2021-01-22 味之素株式会社 Compound having affinity substance for antibody and bio-orthogonal functional group, or salt thereof
AU2020266593A1 (en) 2019-05-01 2021-11-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing asthma by administering an IL-33 antagonist
CA3147068A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
SG11202113310UA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
BR112022011098A2 (en) 2019-12-09 2022-09-20 Sanofi Biotechnology METHODS FOR TREATMENT OF DIGITALLY IDENTIFIED IL-4/IL-13-RELATED DISORDERS
KR20220158821A (en) 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
EP4153300A1 (en) 2020-05-22 2023-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
KR20230130681A (en) 2021-01-08 2023-09-12 리제너론 파아마슈티컬스, 인크. Method of treating peanut allergy by administration of IL-4R antagonist and method of strengthening peanut allergen-specific immunotherapy

Also Published As

Publication number Publication date
IL286470A (en) 2021-10-31
US20200345843A1 (en) 2020-11-05
JP2022526738A (en) 2022-05-26
MA55372A (en) 2022-01-26
AU2020240132A1 (en) 2021-09-16
KR20210143246A (en) 2021-11-26
CO2021013993A2 (en) 2021-12-10
MX2021011141A (en) 2022-01-19
US11964016B2 (en) 2024-04-23
WO2020191346A1 (en) 2020-09-24
CA3132587A1 (en) 2020-09-24
CN113597328A (en) 2021-11-02
BR112021018627A2 (en) 2021-11-23
EP3941589A1 (en) 2022-01-26
CL2021002410A1 (en) 2022-04-29

Similar Documents

Publication Publication Date Title
IL286470A (en) Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
IL283592A (en) Inhibitors of apol1 and methods of using same
IL287768A (en) Kcnt1 inhibitors and methods of use
IL287751A (en) Kcnt1 inhibitors and methods of use
EP3151832A4 (en) Methods of increasing tonic inhibition and treating secondary insomnia
EP4143196A4 (en) PI3K-a INHIBITORS AND METHODS OF USE THEREOF
IL285927A (en) Combinations of rad51 and parp inhibitors
IL287973A (en) Acss2 inhibitors and methods of use thereof
EP3706737A4 (en) Ash1l inhibitors and methods of treatment therewith
IL285525A (en) Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
EP3986894A4 (en) Ectonucleotidase inhibitors and methods of use thereof
IL310812A (en) Solid forms of spirotricyclic apol1 inhibitors and methods of using same
EP3389620A4 (en) Stem cell stimulating compositions and methods of treating melasma
EP3959197A4 (en) Papd5 inhibitors and methods of use thereof
IL286149A (en) Caspase inhibitors and methods of use thereof
IL264854A (en) Spt5 inhibitors and methods of use thereof
IL299700A (en) Kcnt1 inhibitors and methods of use
EP4110317A4 (en) Kcnt1 inhibitors and methods of use
EP3968994C0 (en) Abhd12 inhibitors and methods of making and using same
EP3813784A4 (en) Prc1 inhibitors and methods of treatment therewith
IL299840A (en) Inhibitors of complement factors and uses thereof
IL287066A (en) Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
IL286699A (en) Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers
IL311027A (en) Il-13 inhibitors for the treatment of prurigo nodularis
IL291547A (en) Quinoline inhibitors of rad52 and methods of use